Novartis AG (SWX:NOVN)
129.58
-1.74 (-1.33%)
Sep 4, 2026, 5:31 PM CET
Novartis AG Revenue
Novartis AG had revenue of $14.95B USD in the quarter ending June 30, 2026, with 0.78% growth. This brings the company's revenue in the last twelve months to $56.69B, up 21.50% year-over-year. In the year 2025, Novartis AG had annual revenue of $56.67B with 9.57% growth.
Revenue (ttm)
$56.69B
Revenue Growth
+21.50%
P/S Ratio
5.38
Revenue / Employee
$753.23K
Employees
75,267
Market Cap
246.29B CHF
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.67B | 4.95B | 9.57% |
| Dec 31, 2024 | 51.72B | 5.06B | 10.85% |
| Dec 31, 2023 | 46.66B | 3.20B | 7.36% |
| Dec 31, 2022 | 43.46B | -513.00M | -1.17% |
| Dec 31, 2021 | 43.97B | -5.92B | -11.87% |
| Dec 31, 2020 | 49.90B | 1.22B | 2.51% |
| Dec 31, 2019 | 48.68B | 2.58B | 5.59% |
| Dec 31, 2018 | 46.10B | 2.70B | 6.21% |
| Dec 31, 2017 | 43.40B | -6.03B | -12.20% |
| Dec 31, 2016 | 49.44B | -951.00M | -1.89% |
| Dec 31, 2015 | 50.39B | -3.25B | -6.05% |
| Dec 31, 2014 | 53.63B | 918.00M | 1.74% |
| Dec 31, 2013 | 52.72B | 745.00M | 1.43% |
| Dec 31, 2012 | 51.97B | -7.40B | -12.47% |
| Dec 31, 2011 | 59.38B | 7.81B | 15.15% |
| Dec 31, 2010 | 51.56B | 6.46B | 14.32% |
| Dec 31, 2009 | 45.10B | 2.52B | 5.92% |
| Dec 31, 2008 | 42.58B | 3.64B | 9.34% |
| Dec 31, 2007 | 38.95B | 3.84B | 10.94% |
| Dec 31, 2006 | 35.11B | 5.35B | 17.99% |
| Dec 31, 2005 | 29.75B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Roche Holding AG | 62.96B |
| Sandoz Group AG | 9.43B |
| Alcon | 8.78B |
| Lonza Group AG | 6.87B |
| Galderma Group AG | 4.79B |
| Galenica AG | 4.29B |
| Sonova Holding AG | 3.61B |
| Straumann Holding AG | 2.64B |
Novartis AG News
- 1 day ago - A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares? - Barrons
- 1 day ago - Novartis' Pelacarsen Fails To Meet Primary Endpoint In Phase III Lp(a)HORIZON Trial - Nasdaq
- 1 day ago - A highly anticipated cholesterol drug from Novartis failed to reduce the risk of severe cardiovascular outcomes in a Phase 3 study - WSJ
- 1 day ago - Novartis Says Pelacarsen Heart Disease Drug Missed Primary Endpoint - WSJ
- 1 day ago - Novartis, Ionis Tumble On Surprise Flop For Heart Drug - Investor's Business Daily
- 1 day ago - Ionis, Novartis' key experimental heart drug fails in late-stage trial - Reuters
- 1 day ago - Novartis announces Phase 3 pelacarsen study did not meet primary endpoint - TheFly
- 2 days ago - Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals - Nasdaq